GH1 and hepatocellular carcinoma: While we are aware that our therapeutic studies in patients represent a limited experience, these studies are relevant because they show potential clinical efficacy that warrants further investigation in future large, randomized, clinical trials by integrating pegvisomant into front- and second-line settings in HCC patients with high GH levels.